Dimensional Fund Advisors
CRVS icon

Dimensional Fund Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Dimensional Fund Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,793
Closed -$72.5K – 3284
2025
Q1 		$72.5K Hold
22,793
– – ﹤0.01% 3236
2024
Q4 		$122K Buy
22,793
+10,869
+91% +$81.1K ﹤0.01% 3219
2024
Q3 		$63K Hold
11,924
– – ﹤0.01% 3276
2024
Q2 		$21.7K Hold
11,924
– – ﹤0.01% 3347
2024
Q1 		$21.2K Hold
11,924
– – ﹤0.01% 3365
2023
Q4 		$21K Sell
11,924
-2,966
-20% -$4.34K ﹤0.01% 3387
2023
Q3 		$21.7K Sell
14,890
-43,222
-74% -$91.4K ﹤0.01% 3440
2023
Q2 		$133K Buy
+58,112
New +$121K ﹤0.01% 3293
2022
Q3 		$30K Sell
37,051
-195,766
-84% -$187K ﹤0.01% 3447
2022
Q2 		$231K Sell
232,817
-186,323
-44% -$229K ﹤0.01% 3231
2022
Q1 		$687K Sell
419,140
-55,941
-12% -$102K ﹤0.01% 3077
2021
Q4 		$1.15M Buy
475,081
+295,047
+164% +$1.14M ﹤0.01% 2998
2021
Q3 		$874K Sell
180,034
-215,795
-55% -$639K ﹤0.01% 3071
2021
Q2 		$1.06M Sell
395,829
-20,820
-5% -$57.3K ﹤0.01% 3018
2021
Q1 		$1.28M Sell
416,649
-19,559
-4% -$70.7K ﹤0.01% 2961
2020
Q4 		$1.55M Hold
436,208
– – ﹤0.01% 2879
2020
Q3 		$1.75M Sell
436,208
-2,175
-0.5% -$8.69K ﹤0.01% 2779
2020
Q2 		$1.19M Hold
438,383
– – ﹤0.01% 2893
2020
Q1 		$925K Sell
438,383
-16,288
-4% -$66.1K ﹤0.01% 2921
2019
Q4 		$2.47M Sell
454,671
-19,963
-4% -$69.8K ﹤0.01% 2805
2019
Q3 		$1.43M Buy
474,634
+6,100
+1% +$25.6K ﹤0.01% 2941
2019
Q2 		$1.75M Buy
468,534
+47,254
+11% +$185K ﹤0.01% 2935
2019
Q1 		$1.69M Buy
421,280
+84,953
+25% +$359K ﹤0.01% 2929
2018
Q4 		$1.23M Buy
336,327
+75,626
+29% +$516K ﹤0.01% 2968
2018
Q3 		$2.24M Buy
260,701
+104,230
+67% +$1.04M ﹤0.01% 2905
2018
Q2 		$1.72M Buy
156,471
+22,035
+16% +$246K ﹤0.01% 2925
2018
Q1 		$1.55M Buy
134,436
+71,300
+113% +$674K ﹤0.01% 2910
2017
Q4 		$654K Buy
63,136
+41,143
+187% +$527K ﹤0.01% 3057
2017
Q3 		$351K Sell
21,993
-4,450
-17% -$61.6K ﹤0.01% 3148
2017
Q2 		$320K Buy
+26,443
New +$282K ﹤0.01% 3152

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors's CRVS Position: Q2 2025 in Review

Dimensional Fund Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 22,793 shares — an estimated $72.5K sold.

Dimensional Fund Advisors first reported a position in CRVS in Q2 2017 and held it in 30 quarters. The position peaked at $2.47M in Q4 2019. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Dimensional Fund Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Dimensional Fund Advisors sold 22,793 Corvus Pharmaceuticals shares in Q2 2025, an estimated $72.5K.
  • Dimensional Fund Advisors first reported a position in Corvus Pharmaceuticals in Q2 2017 and held it in 30 quarters.
  • Dimensional Fund Advisors's Corvus Pharmaceuticals position peaked at $2.47M in Q4 2019.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Dimensional Fund Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.